This resource links to the American Association for the Treatment of Opioid Dependence (AATOD) guidelines for addressing benzodiazepine use in Opioid Treatment Programs (OTPs). These guidelines offer practical considerations for managing benzodiazepine use among patients receiving opioid agonist treatment and promote clinical approaches that balance safety with individualized care.
Access AATOD’s guidelines on addressing benzodiazepine use within OTP settings — a resource for clinical teams and administrators on practical considerations, risk management, and treatment planning.
Key takeaways
- Risk awareness: Benzodiazepines can significantly increase sedation and respiratory depression when combined with opioid agonists.
- Clinical caution: Benzodiazepine use is not an absolute contraindication but requires careful assessment and monitoring.
- Management strategies: Guidelines promote individualized treatment planning with appropriate education and documentation.
What’s inside
- Background on benzodiazepine risks in opioid treatment contexts
- Recommendations for assessment and risk mitigation
- Guidance on patient education and documentation
- Clinical considerations for monitoring and treatment planning
- Notes on admission and tapering approaches when indicated
Need help?
If you have questions about applying these guidelines in your program or need assistance interpreting guideline recommendations, contact NJATOD at in**@****od.org.
